Tweet
Source: http://www.cidrap.umn.edu/news-persp...an-jan-24-2020
Stewardship / Resistance Scan for Jan 24, 2020
BARDA funding for new C diff drug; Investing to tackle antibiotic resistance
Filed Under:
Antimicrobial Stewardship; Clostridium difficile
BARDA boosts funding for development of new C difficile antibiotic
Summit Therapeutics yesterday announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded the company an additional $8.8 million for clinical and regulatory development of an investigational antibiotic for treating Clostridiodes difficile infection (CDI).
The additional funding is for a new clinical trial for ridinilazole in adolescent patients. Ridinilazole is a oral small-molecule antibiotic designed to selectively kill C difficile bacteria and preserve patients' beneficial gut bacteria, leading to sustained CDI cures. Summit, of Cambridge, Mass., says the adolescent trial is expected to support a New Drug Application for ridinilazole.
The award brings BARDA's total committed funding for the project to $62.4 million.
"BARDA's continued support for ridinilazole is instrumental in helping to bring this potential CDI treatment option to patients, whose current treatment options fail to sustain cures for one third of the population," Glyn Edwards, CEO of Summit, said in a company press release. "We thank BARDA for its commitment to ridinilazole, innovation and public health."
The Centers for Disease Control and Prevention estimates that there were 223,900 CDI cases in hospitalized patients in 2017, 12,800 CDI-related deaths, and $1 billion in attributable healthcare costs.
Jan 23 Summit Therapeutics press release
Initiative aims to mobilize investors in fight against drug resistance
At the World Economic Forum in Davos yesterday, a coalition of public and private-sector organizations announced an effort to engage the financial sector in tackling antimicrobial resistance (AMR).
The aim of the "Investor Year of Action on AMR" is to "leverage influence to make change happen," according to a press release from the Farm Animal Investment Risk & Return (FAIRR) initiative, which is one of the groups backing the effort. During the year-long initiative, investors will be encouraged to assess and integrate risks, opportunities, and impacts, and make investment decisions, with AMR in mind.
Other groups involved in the initiative include the UK Department of Health and Social Care, the Access to Medicines Foundation, and Principles for Responsible Investment (PRI).
"The World Bank believes AMR could cause greater economic damage than the 2008 financial crisis, potentially decreasing global annual GDP by up to 3.8% by 2050," said Fiona Reynolds, chief executive of PRI. "If investors fail to take action on antimicrobial resistance, the public health consequences could be catastrophic and entire sectors from food to pharmaceuticals face industry-wide risk. The investor year of action on AMR is a timely and important initiative that capital markets cannot afford to ignore."
Jan 23 FAIRR press release
Stewardship / Resistance Scan for Jan 24, 2020
BARDA funding for new C diff drug; Investing to tackle antibiotic resistance
Filed Under:
Antimicrobial Stewardship; Clostridium difficile
BARDA boosts funding for development of new C difficile antibiotic
Summit Therapeutics yesterday announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded the company an additional $8.8 million for clinical and regulatory development of an investigational antibiotic for treating Clostridiodes difficile infection (CDI).
The additional funding is for a new clinical trial for ridinilazole in adolescent patients. Ridinilazole is a oral small-molecule antibiotic designed to selectively kill C difficile bacteria and preserve patients' beneficial gut bacteria, leading to sustained CDI cures. Summit, of Cambridge, Mass., says the adolescent trial is expected to support a New Drug Application for ridinilazole.
The award brings BARDA's total committed funding for the project to $62.4 million.
"BARDA's continued support for ridinilazole is instrumental in helping to bring this potential CDI treatment option to patients, whose current treatment options fail to sustain cures for one third of the population," Glyn Edwards, CEO of Summit, said in a company press release. "We thank BARDA for its commitment to ridinilazole, innovation and public health."
The Centers for Disease Control and Prevention estimates that there were 223,900 CDI cases in hospitalized patients in 2017, 12,800 CDI-related deaths, and $1 billion in attributable healthcare costs.
Jan 23 Summit Therapeutics press release
Initiative aims to mobilize investors in fight against drug resistance
At the World Economic Forum in Davos yesterday, a coalition of public and private-sector organizations announced an effort to engage the financial sector in tackling antimicrobial resistance (AMR).
The aim of the "Investor Year of Action on AMR" is to "leverage influence to make change happen," according to a press release from the Farm Animal Investment Risk & Return (FAIRR) initiative, which is one of the groups backing the effort. During the year-long initiative, investors will be encouraged to assess and integrate risks, opportunities, and impacts, and make investment decisions, with AMR in mind.
Other groups involved in the initiative include the UK Department of Health and Social Care, the Access to Medicines Foundation, and Principles for Responsible Investment (PRI).
"The World Bank believes AMR could cause greater economic damage than the 2008 financial crisis, potentially decreasing global annual GDP by up to 3.8% by 2050," said Fiona Reynolds, chief executive of PRI. "If investors fail to take action on antimicrobial resistance, the public health consequences could be catastrophic and entire sectors from food to pharmaceuticals face industry-wide risk. The investor year of action on AMR is a timely and important initiative that capital markets cannot afford to ignore."
Jan 23 FAIRR press release